Effect of soy protein supplementation in patients with chronic hepatitis C: A randomized clinical trial

Table 4 Median values of biochemical tests in patients with hepatitis C virus after protein supplementation

	CG-casein		IG-soy		Treatment difference
Exams	n	median (iq r)	n	median (iq r)	P value1
Total cholesterol (mg/dL)	80	152.0 (61.5)	80	153.0 (44.7)	0.54
HDL (mg/dL)	80	46.0 (17.0)	80	43.5 (15.2)	0.21
LDL (mg/dL)	80	89.5 (45.0)	80	84.5 (41.5)	0.39
AST (U/L)	78	61.5 (40.5)	80	49.5 (44.2)	0.02
ALT (U/L)	78	73.0 (65.7)	79	64.0 (50.0)	0.007
γGT (U/L)	75	108.0 (120.5)	73	84.0 (107.0)	0.09
HOMA-IR	79	2.4 (2.7)	80	2.6 (2.2)	0.91

¹Mann-Whitney test (P < 0.05): comparison between groups; Bonferroni correction (P < 0.007); CG-casein: Control group-casein; IG-soy: Intervention group-soy; iq r: Interquartile range; n < 80: When an examination was not performed; HOMA-IR: Homeostasis model assessment index of insulin resistance; HDL: High density lipoprotein; LDL: Low density lipoprotein; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; γGT: Gamma glutamyl transferase.